Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.
Inclusion Criteria:
- All consecutive patients with COVID-19 infection admitted to the ICU or hospitalized
because of severe form (eg: hypoxia, orthopnea, pneumonitis, kidney insufficiency) will be
included
Exclusion Criteria:
- Patients under 18 years
Centre Hospitalier de Cannes
Cannes, France
CHU de Dijon
Dijon, France
Centre Hospitalier de Draguignan
Draguignan, France
Centre Hospitalier de Grasse
Grasse, France
Clinique Ambroise-Paré
Neuilly, France
CHU de Nice
Nice, France
Hôpitaux Universitaires Paris Centre - Hôpital Cochin
Paris, France
CHU de REIMS
Reims, France
Denis DOYEN
0033492035510
doyen.d@chu-nice.fr
Denis DOYEN, Principal Investigator
CHU de NICE - Archet 1